Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed against this antigen are also disclosed.
1. A method of inhibiting growth of cancerous cells in a human individual comprising administering to the individual an effective amount of a composition comprising: (i) a chimeric or humanized antibody and (ii) a pharmaceutically acceptable excipient, wherein:
(A) said chimeric or humanized antibody comprises the three complementarity determining regions (CDRs) from the heavy chain and the three complementarity determining regions (CDRs) from the light chain of antibody mPA7 produced by a host cell with a deposit number of ATCC No. PTA-3706, and further comprises constant regions sufficient to induce an active immune response against cancerous cells
(B) said chimeric or humanized antibody specifically binds to the human CD46 antigen at the epitope recognized by antibody mPA7;
wherein said cancerous cells express said human CD46 antigen having the epitope recognized by antibody mPA7 on their cell surface, and bind said chimeric or humanized antibody, which induces an active immune response against said cancerous cells and inhibits their growth.
2. The method of claim 1 , wherein the antibody is linked to a therapeutic agent.
3. The method of claim 1 , wherein the cancerous cells are prostate.
4. The method of claim 1 , wherein the antibody is a humanized antibody that comprises said three CDRs from the heavy chain and said three CDRs of the light chain of antibody mPA7 grafted into a human supporting framework region.
5. The method of claim 1 , wherein the antibody is a chimeric antibody that comprises heavy chain and light chain constant regions from constant regions of a human antibody.
6. The method of claim 2 , wherein the therapeutic agent is a toxin, a radioactive compound, or a chemotherapeutic agent.